Publications

• 1. Ritchlin CT
  2. Coates LC
  3. McInnes IB
  4. Mease PJ
  5. Merola JF
  6. Tanaka Y
  7. Asahina A
  8. Gossec L
  9. Gottlieb AB
  10. Warren RB
  11. Ink B
  12. Bajracharya R
  13. Shende V
  14. Coarse J
  15. Landewé RB
  Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.; Annals of the rheumatic diseases. 2023 Sep 11.
• 1. Kenney HM
  2. Rangel-Moreno J
  3. Peng Y
  4. Chen KL
  5. Bruno J
  6. Embong A
  7. Pritchett E
  8. Fox JI
  9. Becerril-Villanueva E
  10. Gamboa-Domínguez A
  11. Quataert S
  12. Muthukrishnan G
  13. Wood RW
  14. Korman BD
  15. Anolik JH
  16. Xing L
  17. Ritchlin CT
  18. Schwarz EM
  19. Wu CL
  Multi-omics analysis identifies IgG2b class-switching with ALCAM-CD6 co-stimulation in joint-draining lymph nodes during advanced inflammatory-erosive arthritis.; Frontiers in immunology; Vol 14, pp. 1237498. 2023 Aug 25.
• 1. Siebert S
  2. Sweet KM
  3. Ritchlin CT
  4. Hsia EC
  5. Kollmeier AP
  6. Xu XL
  7. Seridi L
  8. Song Q
  9. Gao S
  10. Chen W
  11. Miron M
  Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Trials.; ACR open rheumatology. 2023 Aug 08.
• 1. Bawany F
  2. Ryan Wolff J
  3. Ritchlin CT
  4. Tausk F
  Home Phototherapy Improves Access to Dermatologic Care: A Novel Stakeholder Alliance to Facilitate Its Implementation.; Clinical, cosmetic and investigational dermatology; Vol 16, pp. 1175-1180. 2023 May 02.
• 1. Leung YY
  2. Kavanaugh A
  3. Ritchlin CT
  Expert Perspective: Management of the Psoriatic Arthritis Patient After Failure of One Anti-TNF inhibitor.; Arthritis & rheumatology (Hoboken, N.J.). 2023 Mar 16.
• 1. McGonagle D
  2. McInnes IB
  3. Deodhar A
  4. Schett G
  5. Shawi M
  6. Chakravarty SD
  7. Kollmeier AP
  8. Xu XL
  9. Sheng S
  10. Xu S
  11. Ritchlin CT
  12. Rahman P
  13. Mease PJ
  Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies.; ACR open rheumatology. 2023 Mar 07.
• 1. Kenney HM
  2. Dieudonne G
  3. Yee S
  4. Maki JH
  5. Wood RW
  6. Schwarz EM
  7. Ritchlin CT
  8. Rahimi H
  Near-Infrared Imaging of Indocyanine Green Identifies Novel Routes of Lymphatic Drainage from Metacarpophalangeal Joints in Healthy Human Hands.; Lymphatic research and biology. 2023 Feb 20.
• 1. Ritchlin CT
  2. Deodhar A
  3. Boehncke WH
  4. Soriano ER
  5. Kollmeier AP
  6. Xu XL
  7. Zazzetti F
  8. Shawi M
  9. Jiang Y
  10. Sheng S
  11. Helliwell PS
  Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.; ACR open rheumatology. 2023 Feb 10.
• 1. Kenney HM
  2. Wood RW
  3. Ramirez G
  4. Bell RD
  5. Chen KL
  6. Schnur L
  7. Rahimi H
  8. Korman BD
  9. Xing L
  10. Ritchlin CT
  11. Schwarz EM
  12. Cole CL
  Implementation of automated behavior metrics to evaluate voluntary wheel running effects on inflammatory-erosive arthritis and interstitial lung disease in TNF-Tg mice.; Arthritis research & therapy; Vol 25(1), pp. 17. 2023 Feb 02.
• 1. Kenney HM
  2. Peng Y
  3. de Mesy Bentley KL
  4. Xing L
  5. Ritchlin CT
  6. Schwarz EM
  The Enigmas of Lymphatic Muscle Cells: Where Do They Come From, How Are They Maintained, and Can They Regenerate?; Current rheumatology reviews. 2023 Jan 27.
• 1. Ritchlin CT
  2. Coates LC
  3. Mease PJ
  4. van der Heijde D
  5. Song J
  6. Jiang Y
  7. Shawi M
  8. Kollmeier AP
  9. Rahman P
  The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.; Trials; Vol 24(1), pp. 22. 2023 Jan 10.
• 1. Kenney HM
  2. Peng Y
  3. Bell RD
  4. Wood RW
  5. Xing L
  6. Ritchlin CT
  7. Schwarz EM
  Persistent popliteal lymphatic muscle cell coverage defects despite amelioration of arthritis and recovery of popliteal lymphatic vessel function in TNF-Tg mice following anti-TNF therapy.; Scientific reports; Vol 12(1), pp. 12751. 2022 Jul 26.
• 1. Coates LC
  2. McInnes IB
  3. Merola JF
  4. Warren RB
  5. Kavanaugh A
  6. Gottlieb AB
  7. Gossec L
  8. Assudani D
  9. Bajracharya R
  10. Coarse J
  11. Ink B
  12. Ritchlin CT
  Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study.; Arthritis & rheumatology (Hoboken, N.J.). 2022 Jul 13.
• 1. Orbai AM
  2. Coates LC
  3. Deodhar A
  4. Helliwell PS
  5. Ritchlin CT
  6. Leibowitz E
  7. Kollmeier AP
  8. Hsia EC
  9. Xu XL
  10. Sheng S
  11. Jiang Y
  12. Liu Y
  13. Han C
  Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.; The patient. 2022 Jun 30.
• 1. Coates LC
  2. Ritchlin CT
  3. Gossec L
  4. Helliwell PS
  5. Rahman P
  6. Kollmeier AP
  7. Xu XL
  8. Shawi M
  9. Karyekar CS
  10. Contré C
  11. Noël W
  12. Sheng S
  13. Wang Y
  14. Xu S
  15. Mease PJ
  Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.; Rheumatology (Oxford, England). 2022 Jun 29.
• 1. Stober C
  2. McInnes IB
  3. Raychaudhuri S
  4. Mease PJ
  5. Pennington SR
  6. Scher JU
  7. Chandran V
  8. Armstrong AW
  9. de Wit M
  10. Cauli A
  11. Jadon DR
  12. Löve TJ
  13. Ogdie A
  14. O'Sullivan D
  15. van Mens LJJ
  16. Ritchlin CT
  17. FitzGerald O
  Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting.; The Journal of rheumatology. 2022 Apr 01.
• 1. Rangel-Moreno J
  2. Garcia-Hernandez ML
  3. Owen T
  4. Barnard J
  5. Becerril-Villanueva E
  6. Kashyap T
  7. Argueta C
  8. Gamboa-Dominguez A
  9. Tamir S
  10. Landesman Y
  11. Goldman BI
  12. Ritchlin CT
  13. Anolik JH
  Small molecule inhibitors of nuclear export ameliorate lupus by modulating plasma cell generation and survival.; Arthritis & rheumatology (Hoboken, N.J.). 2022 Mar 25.
• 1. Kenney HM
  2. Wu CL
  3. Loiselle AE
  4. Xing L
  5. Ritchlin CT
  6. Schwarz EM
  Single-cell transcriptomics of popliteal lymphatic vessels and peripheral veins reveals altered lymphatic muscle and immune cell populations in the TNF-Tg arthritis model.; Arthritis research & therapy; Vol 24(1). 2022 Mar 07.
• 1. Ritchlin CT
  2. Mease PJ
  3. Boehncke WH
  4. Tesser J
  5. Schiopu E
  6. Chakravarty SD
  7. Kollmeier AP
  8. Xu XL
  9. Shawi M
  10. Jiang Y
  11. Sheng S
  12. Wang Y
  13. Xu S
  14. Merola JF
  15. McInnes IB
  16. Deodhar A
  Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.; RMD open; Vol 8(1). 2022 Mar.
• 1. Garcia-Hernandez ML
  2. Rangel-Moreno J
  3. Garcia-Castaneda M
  4. Kenney HM
  5. Paine A
  6. Thullen M
  7. Anandarajah AP
  8. Schwarz EM
  9. Dirksen RT
  10. Ritchlin CT
  Dendritic cell-specific transmembrane protein is required for synovitis and bone resorption in inflammatory arthritis.; Frontiers in immunology; Vol 13, pp. 1026574. 2022 Jan 07.
• 1. McInnes IB
  2. Asahina A
  3. Coates LC
  4. Landewé R
  5. Merola JF
  6. Ritchlin CT
  7. Tanaka Y
  8. Gossec L
  9. Gottlieb AB
  10. Warren RB
  11. Ink B
  12. Assudani D
  13. Bajracharya R
  14. Shende V
  15. Coarse J
  16. Mease PJ
  Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).; Lancet (London, England). 2022 Jan 05.
• 1. Merola JF
  2. Landewé R
  3. McInnes IB
  4. Mease PJ
  5. Ritchlin CT
  6. Tanaka Y
  7. Asahina A
  8. Behrens F
  9. Gladman DD
  10. Gossec L
  11. Gottlieb AB
  12. Thaçi D
  13. Warren RB
  14. Ink B
  15. Assudani D
  16. Bajracharya R
  17. Shende V
  18. Coarse J
  19. Coates LC
  Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).; Lancet (London, England). 2022 Jan 05.
• 1. Pournara E
  2. Kormaksson M
  3. Nash P
  4. Ritchlin CT
  5. Kirkham BW
  6. Ligozio G
  7. Pricop L
  8. Ogdie A
  9. Coates LC
  10. Schett G
  11. McInnes IB
  Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis.; RMD open; Vol 7(3). 2021 Nov.
• 1. Kolbinger F
  2. Di Padova F
  3. Deodhar A
  4. Hawkes JE
  5. Huppertz C
  6. Kuiper T
  7. McInnes IB
  8. Ritchlin CT
  9. Rosmarin D
  10. Schett G
  11. Carballido JM
  12. Häusermann P
  13. Calonder C
  14. Vogel B
  15. Rondeau JM
  16. Bruin G
  Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.; Pharmacology & therapeutics. 2021 Jun 22.
• 1. Ritchlin CT
  2. Armstrong A
  3. Johnsson H
  4. Mulder MLM
  GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations.; The Journal of rheumatology. Supplement; Vol 97. 2021 Jun.
• 1. Stober C
  2. Jadon DR
  3. Armstrong AW
  4. Chandran V
  5. de Wit M
  6. Helliwell PS
  7. Mease PJ
  8. Ogdie A
  9. O'Sullivan D
  10. Pennington SR
  11. Löve T
  12. Cauli A
  13. van Mens L
  14. Waxman R
  15. Scher JU
  16. Barton A
  17. Ritchlin CT
  18. FitzGerald O
  Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.; The Journal of rheumatology. Supplement; Vol 97. 2021 Jun.
• 1. Ogdie A
  2. Ritchlin CT
  Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting.; The Journal of rheumatology. Supplement; Vol 97. 2021 Jun.
• 1. Rahman P
  2. Ritchlin CT
  3. Helliwell PS
  4. Boehncke WH
  5. Mease PJ
  6. Gottlieb AB
  7. Kafka S
  8. Kollmeier AP
  9. Hsia EC
  10. Xu XL
  11. Shawi M
  12. Sheng S
  13. Agarwal P
  14. Zhou B
  15. Ramachandran P
  16. Zhuang Y
  17. McInnes IB
  Pooled Safety Results Through One Year of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis.; The Journal of rheumatology. 2021 May 01.
• 1. McGonagle D
  2. McInnes IB
  3. Deodhar A
  4. Schett G
  5. Shawi M
  6. Kafka S
  7. Karyekar CS
  8. Kollmeier AP
  9. Hsia EC
  10. Xu XL
  11. Sheng S
  12. Agarwal P
  13. Zhou B
  14. Ritchlin CT
  15. Rahman P
  16. Mease PJ
  Resolution of Enthesitis by Guselkumab and Relationships to Disease Burden: 1-Year Results of Two Phase-3 Psoriatic Arthritis Studies.; Rheumatology (Oxford, England). 2021 Apr 06.
• 1. Ogdie A
  2. Ritchlin CT
  Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting.; The Journal of rheumatology. 2021 Feb 15.
• 1. Stober C
  2. Jadon DR
  3. Armstrong AW
  4. Chandran V
  5. de Wit M
  6. Helliwell PS
  7. Mease P
  8. Ogdie A
  9. O'Sullivan D
  10. Pennington SR
  11. Löve T
  12. Cauli A
  13. van Mens L
  14. Waxman R
  15. Scher JU
  16. Barton A
  17. Ritchlin CT
  18. FitzGerald O
  Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.; The Journal of rheumatology. 2021 Feb 15.
• 1. Ritchlin CT
  2. Helliwell PS
  3. Boehncke WH
  4. Soriano ER
  5. Hsia EC
  6. Kollmeier AP
  7. Chakravarty SD
  8. Zazzetti F
  9. Subramanian RA
  10. Xu XL
  11. Zuraw QC
  12. Sheng S
  13. Jiang Y
  14. Agarwal P
  15. Zhou B
  16. Zhuang Y
  17. Shawi M
  18. Karyekar CS
  19. Deodhar A
  Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.; RMD open; Vol 7(1). 2021 Feb.
• 1. Gelfand JM
  2. Armstrong AW
  3. Bell S
  4. Anesi GL
  5. Blauvelt A
  6. Calabrese C
  7. Dommasch ED
  8. Feldman SR
  9. Gladman D
  10. Kircik L
  11. Lebwohl M
  12. Lo Re V
  13. Martin G
  14. Merola JF
  15. Scher JU
  16. Schwartzman S
  17. Treat JR
  18. Van Voorhees AS
  19. Ellebrecht CT
  20. Fenner J
  21. Ocon A
  22. Syed MN
  23. Weinstein EJ
  24. Gondo G
  25. Heydon S
  26. Koons S
  27. Ritchlin CT
  National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.; Journal of the American Academy of Dermatology. 2021 Jan 07.
• 1. Scallan JP
  2. Bouta EM
  3. Rahimi H
  4. Kenney HM
  5. Ritchlin CT
  6. Davis MJ
  7. Schwarz EM
  Ex vivo Demonstration of Functional Deficiencies in Popliteal Lymphatic Vessels From TNF-Transgenic Mice With Inflammatory Arthritis.; Frontiers in physiology; Vol 12. 2021.
• 1. Kenney HM
  2. Bell RD
  3. Masters EA
  4. Xing L
  5. Ritchlin CT
  6. Schwarz EM
  Lineage tracing reveals evidence of a popliteal lymphatic muscle progenitor cell that is distinct from skeletal and vascular muscle progenitors.; Scientific reports; Vol 10(1). 2020 Oct 22.
• 1. Ritchlin CT
  2. Giles JT
  3. Ogdie A
  4. Gomez-Reino JJ
  5. Helliwell P
  6. Young P
  7. Wang C
  8. Wu J
  9. Romero AB
  10. Woolcott J
  11. Stockert L
  Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies.; ACR open rheumatology; Vol 2(10). 2020 Oct.
• 1. Gelfand JM
  2. Armstrong AW
  3. Bell S
  4. Anesi GL
  5. Blauvelt A
  6. Calabrese C
  7. Dommasch ED
  8. Feldman SR
  9. Gladman D
  10. Kircik L
  11. Lebwohl M
  12. Lo Re V
  13. Martin G
  14. Merola JF
  15. Scher JU
  16. Schwartzman S
  17. Treat JR
  18. Van Voorhees AS
  19. Ellebrecht CT
  20. Fenner J
  21. Ocon A
  22. Syed MN
  23. Weinstein EJ
  24. Smith J
  25. Gondo G
  26. Heydon S
  27. Koons S
  28. Ritchlin CT
  National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.; Journal of the American Academy of Dermatology. 2020 Sep 04.
• 1. Hughes CD
  2. van Mens LJJ
  3. Boehncke WH
  4. Ritchlin CT
  GRAPPA Trainees Symposium 2019: A Report from the GRAPPA 2019 Annual Meeting.; The Journal of rheumatology. Supplement; Vol 96. 2020 Jun.
• 1. Ritchlin CT
  2. Pennington SR
  3. Reynolds NJ
  4. FitzGerald O
  Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis.; The Journal of rheumatology. Supplement; Vol 96. 2020 Jun.
• 1. Waxman R
  2. Stober C
  3. Jadon DR
  4. Orbai AM
  5. Chandran V
  6. Ogdie A
  7. Pennington SR
  8. de Wit M
  9. O'Sullivan D
  10. Mease PJ
  11. Armstrong AW
  12. Callis Duffin K
  13. Helliwell PS
  14. van Mens LJJ
  15. Ritchlin CT
  16. FitzGerald O
  Proceedings of the 2019 GRAPPA Collaborative Research Network Meeting.; The Journal of rheumatology. Supplement; Vol 96. 2020 Jun.
• 1. Goel N
  2. Coates LC
  3. De Marco G
  4. Eder L
  5. FitzGerald O
  6. Helliwell PS
  7. Leung YY
  8. Maksymowych WP
  9. Mease PJ
  10. Østergaard M
  11. O'Sullivan D
  12. Poddubnyy D
  13. Ritchlin CT
  14. Gladman DD
  GRAPPA 2019 Project Report.; The Journal of rheumatology. Supplement; Vol 96. 2020 Jun.
• 1. Bell RD
  2. Rahimi H
  3. Kenney HM
  4. Lieberman AA
  5. Wood RW
  6. Schwarz EM
  7. Ritchlin CT
  Altered Lymphatic Vessel Anatomy and Markedly Diminished Lymph Clearance in the Rheumatoid Hand with Active Arthritis.; Arthritis & rheumatology (Hoboken, N.J.). 2020 May 18.
• 1. Bell RD
  2. White RJ
  3. Garcia-Hernandez ML
  4. Wu E
  5. Rahimi H
  6. Marangoni RG
  7. Slattery P
  8. Duemmel S
  9. Nuzzo M
  10. Huertas N
  11. Yee M
  12. O'Reilly MA
  13. Morrell C
  14. Ritchlin CT
  15. Schwarz EM
  16. Korman BD
  TNF Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH).; Arthritis & rheumatology (Hoboken, N.J.). 2020 May 10.
• 1. Ritchlin CT
  Evan Calkins, MD, 1920-2020.; Arthritis & rheumatology (Hoboken, N.J.). 2020 May 06.
• 1. Deodhar A
  2. Helliwell PS
  3. Boehncke WH
  4. Kollmeier AP
  5. Hsia EC
  6. Subramanian RA
  7. Xu XL
  8. Sheng S
  9. Agarwal P
  10. Zhou B
  11. Zhuang Y
  12. Ritchlin CT
  Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.; Lancet (London, England); Vol 395(10230). 2020 Apr 04.
• 1. Ritchlin CT
  2. Kavanaugh A
  3. Merola JF
  4. Schett G
  5. Scher JU
  6. Warren RB
  7. Gottlieb AB
  8. Assudani D
  9. Bedford-Rice K
  10. Coarse J
  11. Ink B
  12. McInnes IB
  Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.; Lancet (London, England); Vol 395(10222). 2020 Feb 08.
• 1. Bell RD
  2. Slattery PN
  3. Wu EK
  4. Xing L
  5. Ritchlin CT
  6. Schwarz EM
  iNOS dependent and independent phases of lymph node expansion in mice with TNF-induced inflammatory-erosive arthritis.; Arthritis research & therapy; Vol 21(1). 2019 Nov 14.
• 1. McInnes IB
  2. Puig L
  3. Gottlieb AB
  4. Ritchlin CT
  5. Song M
  6. You Y
  7. Kafka S
  8. Morgan GJ
  9. Rahman P
  10. Kavanaugh A
  Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials.; The Journal of rheumatology; Vol 46(11). 2019 Nov.
• 1. Wu EK
  2. Henkes ZI
  3. McGowan B
  4. Bell RD
  5. Velez MJ
  6. Livingstone AM
  7. Ritchlin CT
  8. Schwarz EM
  9. Rahimi H
  TNF-Induced Interstitial Lung Disease in a Murine Arthritis Model: Accumulation of Activated Monocytes, Conventional Dendritic Cells, and CD21+/CD23- B Cell Follicles Is Prevented with Anti-TNF Therapy.; Journal of immunology (Baltimore, Md. : 1950). 2019 Oct 28.
• 1. Helliwell PS
  2. Deodhar A
  3. Gottlieb AB
  4. Boehncke WH
  5. Xu XL
  6. Xu S
  7. Wang Y
  8. Hsia EC
  9. Gladman DD
  10. Ritchlin CT
  Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase 2 Trial.; Arthritis care & research. 2019 Aug 17.

View All Publications